Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission.

"I'm incredibly proud to have earned the trust of my colleagues, investors, team, and mentors in solving this complex problem."

Ademuyewo raised the round with support from local investors, including Aileen Allen, an adviser and investor associated with the Houston Angel Network, Mercury, and The Artemis Fund; and Matt Miller, former Liongard product executive, as well as from Houston-based VC firm South Loop Ventures. Techstars and JP Morgan also contributed to the round.

"Lokum has found a way to disrupt an organically inefficient and expensive market with an elegant solution that doesn't just save hospitals time and money, but also increases the pool of specialty providers in a market that is consistently strapped for such expertise," Jerry Varnado, venture partner at South Loop Ventures, adds. "This is what disruption in healthcare looks like — scalable commercial solutions that contribute towards better patient care, and we're happy to be part of Lokum's journey."

Ademuyewo has the idea to start Lokum after her experience as an independent contract nurse anesthetist amid the height of the pandemic as she witnessed third-party recruitment agencies take advantage of medical professionals like herself.

Now, the platform's early pilot, which focuses on clinicians in anesthesiology, has served clients across nearly 200 hospitals and surgery centers in 20 states. Ademuyewo also participated in 2024’s cohort for the Google for Startups Accelerator Program-North America, where she spent 10 weeks developing and building her company and platform.

Houston Community College and its partner received funding that will go toward creating a certificate program that will launch in the fall 2022 semester as part of The Resilient Workforce Collaborative. Photo via HCC

Houston college system snags part of $3.3M investment in resiliency innovation

impact investment

Houston Community College and partners received a $1.8 million grant from JP Morgan Chase this month with the goal of training underserved Houstonians in jobs that will help boost the city's preparedness for the aftermath of natural disasters.

The funds will go toward creating a certificate program that will launch in the fall 2022 semester as part of The Resilient Workforce Collaborative.

“The Resilient Workforce Collaborative brings together the public sector, private sector, higher education institutions, and our nonprofit partners to make transformational change in our most underserved neighborhoods,” Mayor Sylvester Turner says in a statement. “The collaborative complements our efforts within the Complete Communities to prepare low-to-moderate income Houstonians for high-demand jobs and increase the diversity of candidates in the talent pipelines for green careers that will advance our city’s resilience. This resourceful partnership is a welcomed addition to Houston’s workforce development landscape.”

The collaborative will operate out of HCC's Resiliency Center of Excellence, which was first announced in May and is slated to open its $35 million Resiliency Operations Center at HCC's Northeast College in 2024. Other members of the collaborative include City of Houston, Harris County, Workforce Solutions Gulf Coast, Resilience Innovation Hub, American Youth Works, WorkTexas, TRIO Electric, TRIO Education, Memorial Assistance Ministries, South Union CDC, Impact Hub Houston, Neuhaus Education Center, TXRX Labs, Volunteers of America-TX, Wesley Community Center, and JPMorgan Chase.

The program will aim to help residents who come from some of Houston’s most underserved and under-resourced neighborhoods find career opportunities in the clean energy, disaster response, utilities, trades and manufacturing fields. According to HCC, "an important element of the collaborative is employers changing some of their hiring practices to emphasize specialized training certificates over traditional 4-year degrees."

So far, partnering employers include The City of Houston, Harris County and TRIO Electric—and the collaborative is looking for more employers and funders to support its mission.

“This collaborative provides a ‘go-to place’ for Houstonians to learn skills that will lead to good paying jobs. It is a better system because it’s set up to fulfill needs that already exist in the workplace,” HCC Chancellor Cesar Maldonado said in a statement.

HCC and the City of Houston signed a memorandum of understanding in August, on the five-year anniversary of Hurricane Harvey, that the organizations would train 500,000 citizens, employees, small businesses, volunteers, and first responders in new resiliency training programs starting this fall.

At the time, seven courses in resiliency were announced, with an additional 30 courses slated to be added in 2023. The program will be offered at 22 HCC locations.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.